These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 870162)

  • 21. Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) salvage of mechlorethamine, vincristine, prednisone, and procarbazine (MOPP)-resistant advanced Hodgkin's disease.
    Piga A; Ambrosetti A; Todeschini G; Cetto G; Perona G; Cellerino R
    Cancer Treat Rep; 1984; 68(7-8):947-51. PubMed ID: 6204754
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide (ABVD) after failure of MOPP therapy.
    Krikorian JG; Portlock CS; Rosenberg SA
    Cancer; 1978 Jun; 41(6):2107-11. PubMed ID: 77716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined cyclophosphamide vincristine, procarbazine, and prednisone (COPP) therapy of malignant lymphoma. Evaluation of 190 patients.
    Morgenfeld MC; Pavlovsky A; Suarez A; Somoza N; Pavlovsky S; Palau M; Barros CA
    Cancer; 1975 Oct; 36(4):1241-9. PubMed ID: 1100220
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced Hodgkin disease.
    Montoto S; Camós M; López-Guillermo A; Bosch F; Cervantes F; Blandé J; Esteve J; Cobo F; Nomdedeu B; Campo E; Montserrat E
    Cancer; 2000 May; 88(9):2142-8. PubMed ID: 10813727
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) vs. CVPP plus CCNU (CCVPP) in Hodgin's disease.
    Morgenfeld M; Somoza N; Magnasco J; Pavlovsky S; de Bonesana AC; Bezares R; Suárez A; Pileggi J; Lein JM; Macchi A; Calabria SI; Garay GE; de Sica SC; Besuschio S
    Cancer; 1979 May; 43(5):1579-86. PubMed ID: 376095
    [No Abstract]   [Full Text] [Related]  

  • 26. Comparison of two non-cross-resistant combinations (ABVP/LOPP) with COPP plus bleomycin in the treatment of advanced Hodgkin's disease.
    Koza I; Bohunický L; Mociková K; Gyárfás J; Svancárová L; Mardiak J; Spánik S; Fuchsberger P; Thalmeinerová Z; Sufliarsky J
    Neoplasma; 1991; 38(6):583-93. PubMed ID: 1722564
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOPP/ABV/CAD chemotherapy with and without recombinant human granulocyte-macrophage colony stimulating factor in untreated, unfavorable prognosis Hodgkin's disease.
    Riccardi A; Gobbi P; Danova M; Giordano M; Pieresca C; Bertoloni D; Brugnatelli S; Ascari E
    Haematologica; 1993; 78(1):44-8. PubMed ID: 7684012
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of advanced Hodgkin's disease: 10-year experience in the Eastern Cooperative Oncology group.
    Glick JH; Barnes JM; Bakemeier RF; Prosnitz LR; Bennett JM; Neiman RS; Costello W; Orlow EL
    Cancer Treat Rep; 1982 Apr; 66(4):855-70. PubMed ID: 7042087
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.
    Carella AM; Congiu AM; Gaozza E; Mazza P; Ricci P; Visani G; Meloni G; Cimino G; Mangoni L; Coser P
    J Clin Oncol; 1988 Sep; 6(9):1411-6. PubMed ID: 2458439
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
    Takenaka T; Mikuni C; Miura A; Sasaki T; Suzuki H; Hotta T; Hirano M; Fukuhara S; Sugiyama H; Nasu K; Dohi H; Kozuru M; Tomonaga M; Tajima K; Niimi M; Fukuda H; Mukai K; Shimoyama M
    Jpn J Clin Oncol; 2000 Mar; 30(3):146-52. PubMed ID: 10798542
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 32. [Combination chemotherapy of Hodgkin's disease with vincristine, cyclophosphamide, procarbazine, and prednisolone].
    Aiba K; Ogawa M; Inagaki J; Horikoshi N; Ezaki K; Inoue K; Dohmyo M; Nagata T; Miyamoto H; Kobayashi T; Kuraishi Y
    Gan To Kagaku Ryoho; 1982 Nov; 9(11):1928-32. PubMed ID: 6897857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.
    Pavlovsky S; Maschio M; Santarelli MT; Muriel FS; Corrado C; Garcia I; Schwartz L; Montero C; Sanahuja FL; Magnasco O
    J Natl Cancer Inst; 1988 Nov; 80(18):1466-73. PubMed ID: 3184196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lomustine, etoposide, vindesine, and dexamethasone (CEVD) in Hodgkin's lymphoma refractory to cyclophosphamide, vincristine, procarbazine, and prednisone (COPP) and doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD): a multicenter trial of the German Hodgkin Study Group.
    Pfreundschuh MG; Schoppe WD; Fuchs R; Pflüger KH; Loeffler M; Diehl V
    Cancer Treat Rep; 1987 Dec; 71(12):1203-7. PubMed ID: 2446751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New multiple-agent chemotherapy (B-DOPA) for advanced Hodgkin's disease.
    Lokich JJ; Frei E; Jaffe N; Tullis J
    Cancer; 1976 Aug; 38(2):667-71. PubMed ID: 61797
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The use of different drugs and combinations in the treatment of Hodgkin's disease.
    Fairley GH
    Ser Haematol; 1973; 6(2):196-201. PubMed ID: 4784374
    [No Abstract]   [Full Text] [Related]  

  • 37. Induction of chromosome breaks and sister chromatid exchanges in patients with Hodgkin's disease by two combination chemotherapy regimens of different leukemogenic potential.
    Sen P; Bailey NM; Hagemeister FB; Liang JC
    Cancer Res; 1990 Feb; 50(3):558-62. PubMed ID: 1688733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eight-drug combination chemotherapy (MOPP and ABDV) and local radiotherapy for advanced Hodgkin's Disease.
    Case DC; Young CW; Nisce L; Lee BJ; Clarkson BD
    Cancer Treat Rep; 1976 Sep; 60(9):1217-23. PubMed ID: 65221
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of prior radiation therapy and age on the frequency and duration of complete remission among various four-drug treatments for advanced Hodgkin's disease.
    Cooper MR; Pajak TF; Gottlieb AJ; Glicksman AS; Nissen N; Richards F; Bloomfield C; Holland JF
    J Clin Oncol; 1984 Jul; 2(7):748-55. PubMed ID: 6376718
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination chemotherapy in the treatment of advanced Hodgkin's disease.
    Sacks P; Jacobs P; Gale D; Lynch SR; Bothwell TH; Stevens K
    S Afr Med J; 1973 Jun; 47(21):903-7. PubMed ID: 4351107
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.